Xarelto, Pradaxa, and Eliquis are three of four New Oral Anticoagulants (NOACs) that are all fighting with each other and the makers of Warfarin (Coumadin) to become the market leader for medications used for the prevention of serious blood clotting disorders in patients who suffer from a medical condition known as atrial fibrillation (Afib). Afib patients have an irregular heartbeat that can cause large blood clots to form deep within the veins of the legs. These clots can break free of the veins in which they form and travel through the circulatory system to the lungs, where they can cause a deadly tear known as a pulmonary embolism (PE).
As described in a recent industry feature from FiercePharma, in order to prevent these clots from forming, doctors will typically prescribe an oral medication. For many years the gold standard was Warfarin (Coumadin), and this medicine is actually a blood thinner. While it is every effective in treating Afib patients, it is not the most convenient for patients, and there are some risks. If the dose of medication is off, the patient may suffer a serious internal bleeding condition. However, the patient can monitor his or her diet closely, as certain foods affect the rate of Coumadin absorption, and he or she can have regular blood tests to make sure the dosage is correct. Continue reading